Ibrutinib — Dosing in CKD & Dialysis

Ibrutinib (Kinase Inhibitor): renal dosing adjustments, dialyzability (Hemodialysis had no significant effect on ibrutinib pharmacokinetics in one patient on HD (Ohtani 2022, PMID 36278298). The label has no dialysis data.), and renal-relevant safety risk for CKD and dialysis patients. Educational r

Reviewed by Matt · November 16, 2026

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.